Egypt Pharmaceutical Market 2022-2030

    Multi User License - $2,999

    In Stock

    Coming soon




    Due to its significance for human health and social significance, the manufacturing of medicines is a strategic sector.

    Infographics:Egypt Pharmaceutical Market, Egypt Pharmaceutical Market Size, Egypt Pharmaceutical Market Trends, Egypt Pharmaceutical Market Forecast, Egypt Pharmaceutical Market Risks, Egypt Pharmaceutical Market Report, Egypt Pharmaceutical Market Share

    This industry began in Egypt with Tal ‘at Harp and the establishment of the first Egyptian pharmaceutical company in 1939 under the name of “Misr Company for Pharmaceuticals” believing in the strategic importance of a strong national pharmaceutical industry. 


    Every year, billions of dollars are invested in research and development worldwide to support this industry, which aims to increase human ability to face various types of diseases.


    This is evidently reflected in the rising life expectancy of people, especially in industrial countries where medicine production is highly concentrated. 


    Egypt has undergone numerous changes throughout its history and witnessed a wide range of key market players, attracting a large number of investments into the expanding industry, which accounts for approximately 30% of the supply of pharmaceuticals in the MENA market. 




    The Egypt Pharmaceutical Market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.



    The first fixed dose combination triple therapy in one device for asthma has been introduced in Egypt by Novartis Pharma S.A.E. (Novartis Egypt). The goal is to give patients better control over their condition and improve their quality of life.


    The patient journey in Egypt, advancements in therapies for uncontrolled asthma, and the advantages of modern inhalers in promoting greater treatment adherence were brought up for discussion by well-known specialists in respiratory and pulmonology.


    The world’s most common chronic respiratory disease, asthma has a significant negative impact on patients’ health and finances. Asthma affected millions of people worldwide, resulting in deaths. 


    The principal fixed portion blend triple treatment in one gadget in Egypt is exceptionally sure information for patients.With 19% improvement for dual therapy and 43% improvement for triple therapy, these new products have demonstrated their capacity to significantly improve quality of life and reduce exacerbations in comparison to the standard of care.


    New inhalers with new molecules have been introduced into the Egyptian market for both dual therapy and triple therapy inhalers with superior control, mometasone furoate has demonstrated the highest binding affinity.


    Novartis strives to develop treatments for both common and uncommon diseases.”For a very long time, Novartis has placed a high priority on treating respiratory conditions, particularly asthma, which has such a high prevalence rate.


    As a leading respiratory company, Novartis take the responsibilities to improve the lives of people all over the world who suffer from lung conditions very seriously.


    Head of Immunology, Dermatology, and Respiratory Franchise at Novartis Egypt, stated, “Novartis hopes to solve the unmet needs in asthma management, improve treatment outcomes for asthma and other respiratory diseases, and relieve the burden such conditions place on the healthcare sector and society as a whole by prioritising innovation and establishing close partnerships with patients and medical experts.”




    1. What is the average cost per Egypt Pharmaceutical Market right now and how will it change in the next 5-6 years?
    2. Average cost to set up a Pharmaceutical Market  in Egypt?
    3. How many Egypt Pharmaceutical Market are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    4. What is happening in the overall public, globally?
    5. Cost breakup of a Egypt Pharmaceutical Market and key vendor selection criteria
    6. Where is the Egypt Pharmaceutical Market  manufactured? What is the average margin per equipment?
    7. Market share of Egypt Pharmaceutical Market manufacturers and their upcoming products
    8. The most important planned Egypt Pharmaceutical Market in next 2 years
    9. Details on network of major Egypt Pharmaceutical Market and pricing plans
    10. Cost advantage for OEMs who manufacture Egypt Pharmaceutical Market in-house
    11. 5 key predictions for next 5 years in Egypt Pharmaceutical Market
    12. Average B-2-B Egypt Pharmaceutical Market price in all segments
    13. Latest trends in Egypt Pharmaceutical Market by every market segment
    14. The market size (both volume and value) of Egypt Pharmaceutical Market in 2022-2030 and every year in between?
    15. Global production breakup of Egypt Pharmaceutical Market,by suppliers and their OEM relationship
    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2022-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2022-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2022-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2022-2030
    21 Product installation rate by OEM, 2022
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2022
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix



      Your Cart
      Your cart is emptyReturn to Shop